FREQUENTLY ASKED QUESTIONS

 

We’ve taken the liberty of supplying answers to some of the questions we hear most. Got a question we haven’t covered? Feel free to Contact Us.

When compared to competing conventional extraction methods, Radient's platform offers the following competitive advantages:

  • Much faster extraction rates leading to reduced processing time, increased throughputs and reduced processing time;
  • Efficient "single stage" extraction leading to increased overall recovery / yield of valuable active compounds (up to 99%)
  • Reduced heat degradation of sensitive molecules leading to improved products;
  • Improved extraction selectivity and purity leading to novel, differentiated products;
  • Ease of commercial scalability.

Yes. Radient’s extraction method relies on a combination of heat, water, and non-toxic solvents. The main production benefits are due to the continuous-flow nature of our extraction platform, which eliminates closed batch vessels, so there is less stopping and re-starting of material flows.

Yes. We received our Standard Processing License in February 2019. This license allows us to legally possess and process cannabis materials for the purpose of sale to other Canadian Licensed Producers. Radient’s Edmonton R&D Laboratory is also Health Canada approved. 

Radient is in the process of applying for EU-GMP certification for its Edmonton III facility, which is expected to begin initial production at the end of calendar 2020.

Radient understands the need for its partners to keep their Intellectual Property completely confidential and secure. We have worked with many world-leading companies and have in place a strict IP protection program. Please contact us if you have questions about IP.

Because Radient is able to extract more of the valuable compounds in the plant and eliminates certain steps associated with downstream processing, we can minimize any cannabinoid degradation that typically happens during processing. This allows us to produce novel ingredients, extracts, formulations and products that have:

  • a longer shelf life
  • improved taste/flavour/aroma profiles
  • standardized products that can reproducibly ensure exact strength and potency
  • medicinal products with a full plant profile - in line with the “entourage effect”

Our proprietary extraction and downstream processing platform is a highly efficient and cost-effective way to reduce nicotine in tobacco at industrial-scale volumes. Using this method, we can reduce nicotine in tobacco by up to 98% (even more than the FDA is recommending) without affecting the taste, smell, or appearance of the tobacco leaf. It’s also faster than any other processing method.

We use heat, water, and ethanol to quickly extract nicotine from tobacco without damaging it. These harmless solvents are constantly recycled, which helps increase flavour and decrease solvent storage. This continuous-flow processing ability means our extraction units take up far less space than other extraction methods and don’t need to shut down between batches.

RADIENT HAS PROVEN ITS MAP™ TECHNOLOGY IS CAPABLE OF:

  • Nicotine depletion of over 95% across multiple cured tobacco types;
  • Nicotine depletion without altering the physical appearance of the tobacco;
  • Limited removal of compounds linked to flavour, verified by taste panel evaluation; and
  • The potential for nicotine depletion in a continuous-flow system, at industrially-relevant scales.

Yes. In early 2018, the U.S. Food and Drug Administration (FDA) announced a plan to reduce nicotine in cigarettes. Their advanced notice of proposed rulemaking (ANPRM) demonstrated that the FDA is committed to stop incidences of disease and death caused by smoking. Nicotine addiction — a major reason tobacco use is so prevalent worldwide — is an important matter of public health.

Our technology can help, and Radient is exploring the potential of a partnership that would utilize our technology to extract nicotine from tobacco. Part of the benefit of using our technology is that we can achieve nicotine depletion of over 95% across multiple cured tobacco types, without altering the tobacco’s flavour, taste, or smell (verified results as part of a research project with a leading tobacco manufacturer). This can be achieved at industrial-scale volumes and can be incorporated as part of the in-line cigarette manufacturing process, rather than having to resort to more time consuming alternatives, such as replacing existing tobacco crops with genetically modified crops.